Compare RBCAA & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | RBCAA | RAPP |
|---|---|---|
| Founded | 1974 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1998 | 2024 |
| Metric | RBCAA | RAPP |
|---|---|---|
| Price | $91.50 | $38.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $48.50 |
| AVG Volume (30 Days) | 105.5K | ★ 374.3K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | ★ 24.34 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | N/A |
| Revenue This Year | $3.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $120.53 | ★ N/A |
| Revenue Growth | ★ 8.50 | N/A |
| 52 Week Low | $63.97 | $13.43 |
| 52 Week High | $92.90 | $43.76 |
| Indicator | RBCAA | RAPP |
|---|---|---|
| Relative Strength Index (RSI) | 72.88 | 52.97 |
| Support Level | $67.07 | $33.54 |
| Resistance Level | N/A | $40.61 |
| Average True Range (ATR) | 2.25 | 2.47 |
| MACD | 0.32 | 0.13 |
| Stochastic Oscillator | 83.03 | 42.09 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.